靶向治疗药物在膜性肾病中的研究进展  

Research progress on targeted therapeutic drugs in membranous nephropathy

作　　者：丘宝珍 朱兴华[1] 杜春荔[1] 陈璐[1] Qiu Bao-zhen;Zhu Xing-hua;Du Chun-li;Chen Lu(Department of Nephrology,Meizhou People's Hospital,Meizhou,Guangdong 514031,China)

机构地区：[1]梅州市人民医院肾内科,广东梅州514031

出　　处：《中国现代医学杂志》2024年第22期49-53,共5页China Journal of Modern Medicine

基　　金：广东省医学科研基金项目(No:B20211337)。

摘　　要：膜性肾病是一种常见的成人肾小球疾病,其特征为免疫复合物在肾小球基底膜上的沉积,导致蛋白尿和肾功能减退。近年来,针对膜性肾病的治疗策略发生了显著变化,特别是在靶向治疗药物的开发和应用方面取得了进展。这些靶向治疗主要集中在特定的分子和途径上,提供了一种更为精准的治疗选择,能够直接作用于疾病的病理机制,从而减少传统免疫抑制治疗的副作用,并提高治疗效果。该文检索国内外最新文献,并对靶抗原及相应的靶向治疗药物的相关资料进行整合,希望能为临床治疗提供理论依据。Membranous nephropathy(MN)is a common glomerular disease in adults characterized by the deposition of immune complexes on the glomerular basement membrane,leading to proteinuria and renal function decline.In recent years,there has been a significant shift in the therapeutic strategies for MN,particularly with the development and application of targeted therapeutic drugs.These targeted therapies primarily focus on specific molecules and pathways,offering a more precise treatment option that directly targets the pathological mechanisms of the disease.This approach reduces the side effects associated with traditional immunosuppressive treatments and enhances therapeutic efficacy.This review included the latest literature both domestically and internationally,integrating information on target antigens and corresponding targeted therapeutic drugs,with the goal of providing a theoretical basis for clinical treatment.

关 键 词：膜性肾病 靶抗原 靶向治疗 单克隆抗体 

分 类 号：R692.6[医药卫生—泌尿科学]